Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: A 16-week randomized trial

Journal of Human Hypertension

Volumn 19, Issue 4, 2005, Pages 277-283

  Amador, N ^a   Encarnacion J J ^a   Guízar, Juan M ^a   Rodriguez L ^a   Lopez M ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Heart sympathetic activity; Left ventricular mass; Losartan; Obese subjects

Indexed keywords

LOSARTAN; PRAVASTATIN; SPIRONOLACTONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; ELECTROCARDIOGRAPHY; HEADACHE; HEALTH PROGRAM; HEART LEFT VENTRICLE MASS; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OBESITY; PATIENT SELECTION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SPECTROSCOPY; STATISTICAL SIGNIFICANCE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; XEROSTOMIA;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; DIURETICS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FOLLOW-UP STUDIES; HEART; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; OBESITY; SPIRONOLACTONE; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 17144395106     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001816     Document Type: Article

References (34)

1. Rumantir MS, Vaz M. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17: 1125-1133.
2. Karason K, Molgaard H, Wikstrand J, Sjostryom L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999; 83: 1242-1247.
3. Amador N et al. Leptin and heart sympathetic activity in normotensive obese and non obese subjects. Ital Heart J 2004; 5: 29-35.
4. Levy D et al. Prognostic implications of echocardiographic determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-1566.
5. Amador N et al. Relationship between left ventricular mass and heart sympathetic activity in male obese subjects. Arch Med Res 2004; 35: 54-58.
6. Ferrannini E et al. Insulin. New roles for an ancient hormone. Eur J Clin Invest 1999; 29: 842-852.
7. Carey RM, Siragy HM. Newly recognized components of the rennin-angiotensin system: potential roles and cardiovascular renal regulation. Endocr Rev 2003; 24: 261-271.
8. Casolo G et al. Decreased spontaneous heart rate variability on congestive heart failure. Am J Cardiol 1989; 64 1162-1167.
9. De Ferrari GM, Vanoli E, Schwartz PJ. Cardiac vagal activity, myocardial ischemia and sudden death. In: Zipes DP, Jalife J (eds). Cardiac electrophysiology: From cell to bedside. WB Saunders Co.: Philadelphia, PA, 1995 pp 422-434.
10. Oparil S, Zaman AM, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139: 761-776.
11. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999; 39: 547-559.
12. Chorbanian AV et al. for The National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
13. Vasan RS et al. Assessment of frequency of progression to hypertension in non hypertensive participants in The Framingham Heart Study. Lancet 2001; 358: 1682-1686.
14. Jackson AS, Pollock M. Practical assessment of body composition. Phys Sports Med 1985; 13: 76-90.
15. Devereux RB, Lutas EM, Casale PN. Standardisation of M mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230.
16. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of method. Circulation 1977; 55: 613-618.
17. de Simone G et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
18. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
19. Haffner SM, Miettinem H, Stern MP. The homeostatic model in the San Antonio heart study. Diabetes Care 1997; 20: 1087-1092.
20. Browner WS, Black D, Newman T, Hulley SB. Estimación del tamaño de la muestra y de la potencia. In: Hulley SB, Cummings SR (eds). Diseño de la investigación clínica. DOYMA: Barcelona, España, 1993 pp 153-165.
21. de Simone G et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062.
22. de Simone G et al on behalf of the MAVI Investigators. Prognosis of inappropriate left ventricular mass in hypertension: The MAVI study. Hypertension 2002; 40: 470-476.
23. Messereli FH et al. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983; 74: 808-812.
24. Sakata K et al. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 2002; 20: 103-110.
25. Klein I et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430.
26. Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92 110-114.
27. Kanno Y et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43: 380-386.
28. Unger T, Azizi M, Belz GG. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. J Hum Hypertens 2000; 14(Suppl 2): S23-S31.
29. Glynn RJ et al. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105-110.
30. Celentano A et al. Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens 2002; 20: 531-537.
31. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzime inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study (RALES)). Am J Cardiol 1996; 78: 902-907.
32. McGrath BP et al. Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1990; 16 831-838.
33. Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. Br J Clin Pharmacol 1984; 18: 51-56.
34. Crandall DL, Herzlinger HE, Saunders BD. Developmental aspects of the adipose tissue renin-angiotensin system: therapeutic implicactions. Drug Dev Res 1994; 32: 117-125.